Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Stopped The centers have no longer patients. In September 2018, set up of a competitive international study.
Conditions
Interventions
- DRUG: Roscovitine
- DRUG: Placebo
Sponsor
University Hospital, Brest
Collaborators
- [object Object]
- [object Object]